NAVASYS
DEAD

Serial Number

79167251

Owner

NITTO DENKO CORPORATION

Filing Date

Jan 5, 2015

Add to watchlist:

No watchlists yet
View on USPTO

NAVASYS Trademark

Serial Number: 79167251 • Registration: 4920192

NAVASYS is a trademark filed by NITTO DENKO CORPORATION on January 5, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

NITTO DENKO CORPORATION (179 trademarks)

IBARAKI-SHI, OSAKA-FU , JP

Entity Type: 03

Trademark Details

Filing Date

January 5, 2015

Registration Date

March 22, 2016

Published for Opposition

January 5, 2016

Cancellation Date

January 5, 2025

Goods & Services

Adhesive bands for medical purposes; adhesive plasters for medical purposes; adhesive tapes for medical purposes; adjuvants for medical purposes; bacterial poisons; bacterial preparations for medical or veterinary use; bacteriological preparations for medical or veterinary use; biological preparations for medical purposes for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; biological preparations for veterinary purposes for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; capsules for medicines in the nature of capsules containing medicine for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chemical preparations for medical purposes, namely, for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chemical preparations for pharmaceutical purposes, namely, for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chemical preparations for veterinary purposes, namely, for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations, namely, for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chewing gum for medical purposes; collyrium; medicated compresses; cultures of microorganisms for medical and veterinary purposes; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drugs for medical purposes, namely, pharmaceutical preparations for the prevention of the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; Immunomodulators, namely, lipopolysaccharides, toll-like receptor (TLR) ligands, cyclic dinucleotide, bestatin in the nature of Ubenimex pidotimod as an immunostimulant, levamisole hydrochloride, cyclooxygenase inhibitor, prostaglandin receptor antagonist, prostaglandin receptor agonist, Thymic stromal lymphopoietin (TSLP) production inhibitor, adenylate cyclase inhibitor, omega-3 fatty acid, peroxisome proliferator-activated receptor (PPAR) agonist, dopamine receptor antagonist, dopamine receptor agonist, histamine receptor agonist, histamine receptor antagonist, serotonin receptor agonist, serotonin receptor antagonist, vasopressin receptor antagonist, vasopressin receptor agonist, muscarine receptor antagonist, muscarine receptor agonist, adrenergic receptor antagonist, adrenergic receptor agonist, angiotensin receptor agonist, GABA receptor agonist, thrombin receptor antagonist, thrombin receptor agonist, opioid receptor agonist, Adenosine diphosphate (ADP) receptor agonist, leukotriene receptor antagonist, leukotriene receptor agonist, melatonin receptor agonist, somatostatin receptor agonist, cannabinoid receptor agonist, sphingosine-1 phosphate receptor agonist, metabotropic glutamate receptor agonist, phospholipase A2 inhibitor, TGF-ß production inhibitor, and Th2 cytokine inhibitor all for the treatment and prevention of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; immunosuppressive agent, namely, pharmaceutical preparations in the nature of lipopolysaccharide, toll-like receptor (TLR) ligands, cyclic dinucleotide, bestatin in the nature of Ubenimex pidotimod as an immunostimulant, levamisole hydrochloride, cyclooxygenase inhibitor, prostaglandin receptor antagonist, prostaglandin receptor agonist, Thymic stromal lymphopoietin (TSLP) production inhibitor, adenylate cyclase inhibitor, omega-3 fatty acid, peroxisome proliferator-activated receptor (PPAR) agonist, dopamine receptor antagonist, dopamine receptor agonist, histamine receptor agonist, histamine receptor antagonist, serotonin receptor agonist, serotonin receptor antagonist, vasopressin receptor antagonist, vasopressin receptor agonist, muscarine receptor antagonist, muscarine receptor agonist, adrenergic receptor antagonist, adrenergic receptor agonist, angiotensin receptor agonist, GABA receptor agonist, thrombin receptor antagonist, thrombin receptor agonist, opioid receptor agonist, Adenosine diphosphate (ADP) receptor agonist, leukotriene receptor antagonist, leukotriene receptor agonist, melatonin receptor agonist, somatostatin receptor agonist, cannabinoid receptor agonist, sphingosine-1 phosphate receptor agonist, metabotropic glutamate receptor agonist, phospholipase A2 inhibitor, TGF-ß production inhibitor, and Th2 cytokine inhibitor all for the treatment and prevention of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; lotions for pharmaceutical purposes for skin, mucosal membrane, and body; lotions for veterinary purposes for skin, mucosal membrane, and body; medicated lozenges for pharmaceutical purposes; medical plasters; medicinal drinks; medicines for dental purposes; medicines for human purposes, namely, pharmaceutical preparations for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; medicines for veterinary purposes, namely, pharmaceutical preparations for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; mouthwashes for medical purposes; ointments for pharmaceutical purposes, namely, vaccines; oral vaccine preparations; medicated pastilles for pharmaceutical purposes; petroleum jelly for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for skin care; pomades for medical purposes; poultices; Pharmaceutical preparations for therapy of immunity for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; preparations of microorganisms for medical and veterinary purposes the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; siccatives for medical purposes; sticking plasters for medical purposes; syrups for pharmaceutical purposes for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; therapeutic drug for therapy of immunity, namely, vaccines; tissues impregnated with pharmaceutical lotions for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; vaccine adjuvants; vaccine preparations; vaccines; vaccines against influenza; vaccines against pneumococcal infections; vaccines for cattle; vaccines for dogs; vaccines for horses; vaccines for human or animal; vaccines for human use; vaccines or preparations used in the treatment of cancer; veterinary vaccines

Bacterial preparations other than for medical or veterinary use; biological preparations, other than for medical or veterinary purposes; chemical preparations for analyses in laboratories, namely, chemical preparations for scientific purposes, chemical preparations for use in industry other than for medical or veterinary purposes; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents for scientific purposes other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical substances for analyses in laboratories, namely, chemical preparations for scientific purposes, chemical preparations for use in industry other than for medical or veterinary purposes; chemicals comprising glycolipid structure, namely, glycolipid for use in pharmaceutical preparations; cultures of microorganisms, other than for medical and veterinary use; industrial chemicals; lipopolysaccharide; preparations of microorganisms, namely, cultures of microorganisms, other than for medical and veterinary use

Filing History

DEATH OF INTERNATIONAL REGISTRATION
Aug 1, 2025 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Jul 31, 2023 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jul 11, 2023 INTS
INVALIDATION PROCESSED
Jul 11, 2023 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jun 7, 2023 INTR
CANCELLED SECTION 71
Oct 7, 2022 C71T
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 15, 2016 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 22, 2016 FICS
FINAL DISPOSITION PROCESSED
Jun 22, 2016 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 22, 2016 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 22, 2016 R.PR
PUBLISHED FOR OPPOSITION
Jan 5, 2016 PUBO
NOTIFICATION PROCESSED BY IB
Jan 4, 2016 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 16, 2015 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 16, 2015 OP2R
NOTICE OF PUBLICATION
Dec 16, 2015 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 30, 2015 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 20, 2015 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 20, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 20, 2015 CRFA
ASSIGNED TO LIE
Nov 13, 2015 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 26, 2015 ERFR
FINAL REFUSAL MAILED
Sep 21, 2015 CNFR
FINAL REFUSAL WRITTEN
Sep 18, 2015 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 28, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 28, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 28, 2015 TROA
REFUSAL PROCESSED BY IB
Jul 11, 2015 RFNT
APPLICATION FILING RECEIPT MAILED
Jun 30, 2015 MAFR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 25, 2015 RFCS
REFUSAL PROCESSED BY MPU
Jun 25, 2015 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 25, 2015 RFCR
NON-FINAL ACTION WRITTEN
Jun 24, 2015 CNRT
ASSIGNED TO EXAMINER
Jun 24, 2015 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 24, 2015 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 18, 2015 REPR